TransThera Gets US FDA Fast Track Designation for Prostate Cancer Drug; Shares Up 3%
MT Newswires Live
Jun 24
TransThera Sciences (HKG:2617) said the US Food and Drug Administration has granted fast-track designation for tinengotinib to treat metastatic castration-resistant prostate cancer (mCRPC), according to a Tuesday Hong Kong bourse filing.
In a phase 1/2 study, the drug showed a 46% objective response rate and 85% disease control rate among 13 mCRPC patients with measurable disease, the filing said.
TransThera said the latest designation reflects consistent clinical execution and supports further development of the drug for advanced prostate cancer.
Shares of the clinical-stage biopharmaceutical firm rose about 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.